Market Place
Sourcing Support
Jazz Pharma receive FDA approval for biliary tract cancer treatment
22 Nov 2024 //
REUTERS
Jazz Pharma`s Biologic Ziihera Receives Approval in US
20 Nov 2024 //
FDA
Jazz Pharma to Attend Citi`s 2024 Global Healthcare Conference
19 Nov 2024 //
PR NEWSWIRE
Jazz Pharmaceuticals Announces Q3 2024 Financial Results
06 Nov 2024 //
PR NEWSWIRE
Jazz Pharmaceuticals Presents Xywav® Data at Psych Congress 2024
31 Oct 2024 //
PR NEWSWIRE
Jazz Pharmaceuticals To Report Q3 2024 Financial Results On Nov 6
23 Oct 2024 //
PR NEWSWIRE
Jazz`s almost-withdrawn lung cancer drug shows life
16 Oct 2024 //
PR NEWSWIRE
Denmark`s Lundbeck bets on epilepsy drug with $2.6 bln Longboard deal
15 Oct 2024 //
REUTERS
Jazz HER2 bispecific posts 59% survival at 30 months in gastric cancer
16 Sep 2024 //
FIERCE BIOTECH
Jazz Pharma Presents Zanidatamab Data In Gastroesophageal Cancer
16 Sep 2024 //
PR NEWSWIRE
Jazz Pharma To Present Solid Tumor Research At ESMO 2024
09 Sep 2024 //
PR NEWSWIRE
Jazz Pharma Presents Data on Epidiolex® at European Epilepsy Congress 2024
05 Sep 2024 //
PR NEWSWIRE
Jazz Pharmaceuticals Announces Pricing of $850M Notes and Share Repurchases
03 Sep 2024 //
PR NEWSWIRE
Jazz Pharmaceuticals Announces $850M Senior Notes Offering and Repurchase
03 Sep 2024 //
PR NEWSWIRE
Jazz, Hikma must face `reverse payment` claims over narcolepsy drug
27 Aug 2024 //
REUTERS
Jazz Pharma Updates On Cannabidiol Trial In Japan For Epilepsy
22 Aug 2024 //
PR NEWSWIRE
Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences
21 Aug 2024 //
PR NEWSWIRE
Jazz Pharmaceuticals Reports Q2 2024 Results, Updates 2024 Guidance
31 Jul 2024 //
PR NEWSWIRE
Jazz Pharmaceuticals Shareholders Elect Laura Hamill To Board
25 Jul 2024 //
PR NEWSWIRE
Jazz Pharmaceuticals Completes Loan Repricing And Note Settlement
22 Jul 2024 //
PR NEWSWIRE
Jazz Pharmaceuticals To Report Q2 2024 Results On July 31
17 Jul 2024 //
PR NEWSWIRE
Jazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer
09 Jul 2024 //
PR NEWSWIRE
Jazz`s ph. 2 essential tremor test misses endpoint
21 Jun 2024 //
FIERCE BIOTECH
Takeda`s seizure drug fails to meet main goal in late-stage studies
18 Jun 2024 //
REUTERS
Bispecific, Trispecific Antibodies Market To Grow Robustly By 2035
03 Jun 2024 //
PR NEWSWIRE
ASCO: Jazz shares `unprecedented` biliary tract cancer data
03 Jun 2024 //
FIERCE BIOTECH
Zanidatamab OS Data In Pretreated HER2+ Biliary Tract Cancer At ASCO
01 Jun 2024 //
PR NEWSWIRE
Jazz Highlights Sleep Research At SLEEP 2024 Meeting
30 May 2024 //
PR NEWSWIRE
Zanidatamab Granted Priority Review For HER2+ Biliary Tract Cancer
30 May 2024 //
PR NEWSWIRE
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
29 May 2024 //
PR NEWSWIRE
Jazz, Life Science Cares Partner For Community Wellbeing
22 May 2024 //
PR NEWSWIRE
Jazz Pharma to Fight FDA in Court Over Rival Sleep Drug Approval
09 May 2024 //
BLOOMBERG
Jazz Pharma Q1 2024 Results, Affirms 2024 Guidance
01 May 2024 //
PR NEWSWIRE
Jazz Pharma At BofA Securities 2024 Healthcare Conference
01 May 2024 //
PR NEWSWIRE
Jazz Presents Oncology Pipeline Data at ASCO 2024
24 Apr 2024 //
PR NEWSWIRE
Jazz Pharmaceuticals to Report Q1 2024 Financials on May 1
17 Apr 2024 //
PR NEWSWIRE
Jazz Pharmato Showcase Expansive Neuroscience Portfolio at American Academy
10 Apr 2024 //
PRESS RELAESE
Jazz Completes Zanidatamab BLA for Previously Treated Biliary Tract Cancer
02 Apr 2024 //
PR NEWSWIRE
ADC startup Mythic recruits Jazz exec to lead company; Dyne’s CEO shuffle
28 Mar 2024 //
ENDPTS
Jazz Pharma to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024
12 Mar 2024 //
PR NEWSWIRE
Jazz Announces Full Year and Fourth Quarter 2023 Financial Results
28 Feb 2024 //
PR NEWSWIRE
Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors
27 Feb 2024 //
PR NEWSWIRE
Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer
21 Feb 2024 //
PR NEWSWIRE
Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences
20 Feb 2024 //
PR NEWSWIRE
Jazz Pharma to Report 2023 Full Year and Fourth Quarter Financial Results
14 Feb 2024 //
PR NEWSWIRE
Jazz Pharma and Redx Pharma link up on KRAS inhibitor program
08 Feb 2024 //
PHARMA LETTER
Jazz Pharmaceuticals` PTSD drug fails in mid-stage trial
22 Dec 2023 //
PR NEWSWIRE
Jazz Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
20 Dec 2023 //
PR NEWSWIRE
Jazz Presents Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab
08 Dec 2023 //
PR NEWSWIRE
Jazz to Present Data Emphasizing Commitment to Treatment-Resistant Epilepsy
01 Dec 2023 //
PR NEWSWIRE
Jazz Pharma to Present New Data Highlighting Advancements in Solid Tumors
30 Nov 2023 //
PRESS RELEASE
Jazz halts sleep disorder med trial over `visual disturbances`
29 Nov 2023 //
FIERCE BIOTECH
Jazz puts up $771M to form Autifony neuroscience discovery pact
15 Nov 2023 //
FIERCE BIOTECH
Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results
08 Nov 2023 //
PR NEWSWIRE
Jazz Pharmaceuticals and MD Anderson Announce Five-Year Collaboration
07 Nov 2023 //
PR NEWSWIRE
Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences
01 Nov 2023 //
PR NEWSWIRE
Jazz to Report 2023 Third Quarter Financial Results on November 8, 2023
25 Oct 2023 //
PR NEWSWIRE
Jazz Presents Data Highlighting the Need for Low-Sodium Treatment Option Xywav
23 Oct 2023 //
PR NEWSWIRE
Jazz weighs options, including possible sale: Bloomberg
20 Oct 2023 //
FIERCE PHARMA
